quinazolines has been researched along with Dysmyelopoietic Syndromes in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fulp, WJ; Komrokji, RS; Lancet, JE; List, AF; Padron, E; Rodriguez, Y; Tinsley, S; Yu, D | 1 |
| Erlichman, C; Flynn, PJ; Juckett, MB; Jumonville, A; LaPlant, B; Mattison, R; Moreno-Aspitia, A | 1 |
| Adès, L; Beyne-Rauzy, O; Boehrer, S; Chermat, F; Delaunay, J; Fenaux, P; Hunault, M; Jourdan, E; Kroemer, G; Prebet, T; Raffoux, E; Sebert, M; Seegers, V; Thepot, S; Wattel, E | 1 |
| Schmidt, C | 1 |
| Adès, L; Boehrer, S; de Botton, S; Fenaux, P; Galluzzi, L; Gardin, C; Kroemer, G; Tailler, M; Tajeddine, N | 1 |
| Bouteloup, C; De Botton, S; Enot, D; Fenaux, P; Galluzzi, L; Kroemer, G; Lainey, E; Leroy, C; Marie, N; Micol, JB; Scoazec, M; Wolfromm, A | 1 |
| Fruchtman, SM | 1 |
| Kvasnicka, HM; Ollig, S; Schmitt-Gräff, A; Thiele, J | 1 |
| Caligiuri, MA; Cooper, MR; Curtin, PT; DeAngelo, DJ; Druker, BJ; Heaney, ML; Heinrich, MC; Holford, N; Karol, MD; Klisovic, RB; Lecerf, JM; Nimer, SD; Paquette, RL; Sheng, S; Stone, RM | 1 |
| Hampton, T | 1 |
| Adès, L; Boehrer, S; Braun, T; de Botton, S; Fabre, C; Fenaux, P; Galluzzi, L; Gardin, C; Grosjean, J; Kroemer, G; Le Roux, G; Martin, A | 1 |
1 review(s) available for quinazolines and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Treatment paradigms in the management of myeloproliferative disorders.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Chlorambucil; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myelodysplastic Syndromes; Myeloproliferative Disorders; Philadelphia Chromosome; Platelet Aggregation Inhibitors; Quinazolines; Radiopharmaceuticals | 2004 |
4 trial(s) available for quinazolines and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Azacitidine; Erlotinib Hydrochloride; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Failure | 2014 |
A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Risk Factors; Salvage Therapy; Survival Rate | 2015 |
A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Remission Induction | 2014 |
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Marrow; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-kit; Quinazolines; Receptors, Platelet-Derived Growth Factor | 2006 |
6 other study(ies) available for quinazolines and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Cediranib aims for a comeback.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Female; Humans; Myelodysplastic Syndromes; National Cancer Institute (U.S.); Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Protein-Tyrosine Kinases; Quinazolines; United Kingdom; United States; Uterine Cervical Neoplasms; Vaginal Fistula; Vascular Endothelial Growth Factor A; Weight Loss | 2015 |
Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Cell Differentiation; Cell Line, Tumor; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines | 2008 |
Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Cycle; Cell Differentiation; Cell Line, Tumor; DNA Damage; Drug Synergism; Erlotinib Hydrochloride; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines | 2013 |
Anagrelide does not exert a myelodysplastic effect on megakaryopoiesis: a comparative immunohistochemical and morphometric study with hydroxyurea.
Topics: Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Humans; Hydroxyurea; Immunohistochemistry; Megakaryocytes; Myelodysplastic Syndromes; Quinazolines; Retrospective Studies; Thrombopoiesis | 2005 |
New blood cancer therapies under study.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Aurora Kinases; ErbB Receptors; Erlotinib Hydrochloride; Hematologic Neoplasms; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Myelodysplastic Syndromes; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Rituximab | 2007 |
Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Erlotinib Hydrochloride; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Reference Values | 2008 |